Skip to content
HowShorted

BRAINSTORM CELL THERAPEUTICS INC. short interest in 2019

In 2019, BRAINSTORM CELL THERAPEUTICS INC.'s disclosed short interest ran from 5.31% of shares outstanding on 15 Jan 2019 to 3.28% on 31 Dec 2019, a change of -2.03 percentage points. The year's high was 5.31% on 15 Jan 2019 and its low 1.86% on 28 Jun 2019, averaging 3.70% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 28.75 days on 31 Jan 2019. Full history: BRAINSTORM CELL THERAPEUTICS INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025

Aggregate net short position time series for BRAINSTORM CELL THERAPEUTICS INC. in 2019

2019 in figures

Start of year
5.31% (15 Jan 2019)
End of year
3.28% (31 Dec 2019)
Change
-2.03 pp
High
5.31% (15 Jan 2019)
Low
1.86% (28 Jun 2019)
Average
3.70%
Highest days to cover
28.75 (31 Jan 2019)
SEC filings marked
4

Every report in 2019

BRAINSTORM CELL THERAPEUTICS INC. short interest in 2019
SettlementShort interestDays to coverFilings since previous
15 Jan 20195.31%11.07
31 Jan 20195.28%28.75
15 Feb 20195.22%12.51
28 Feb 20195.04%15.62
15 Mar 20195.24%18.41
29 Mar 20194.71%9.1810-K filed
15 Apr 20194.29%17.02
30 Apr 20194.35%21.01
15 May 20194.08%20.8210-Q filed
31 May 20193.74%19.64
14 Jun 20193.75%25.19
28 Jun 20191.86%4.24
15 Jul 20191.86%4.75
31 Jul 20192.78%5.33
15 Aug 20193.09%1.7410-Q filed
30 Aug 20193.31%12.44
13 Sep 20193.19%9.88
30 Sep 20192.90%14.97
15 Oct 20192.73%13.30
31 Oct 20193.14%15.48
15 Nov 20192.96%15.0110-Q filed
29 Nov 20193.39%8.72
13 Dec 20193.22%12.75
31 Dec 20193.28%5.01

See also: BRAINSTORM CELL THERAPEUTICS INC.'s full history · most shorted US stocks of 2019 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.